Is there a case for n-3 fatty acid supplementation in cystic fibrosis?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 8, Issue 2, 2005, Pages 153-159

  Cawood, Abbie L ^a,c   Carroll, Mary P ^b   Wootton, Stephen A ^a   Calder, Philip C ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cystic fibrosis; Inflammation; n 3 fatty acids

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CHYLOMICRON; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE B5; LINOLEIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; PROSTAGLANDIN E3; PROSTAGLANDIN SYNTHASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG INHIBITION; FATTY ACID METABOLISM; HUMAN; LIPID COMPOSITION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 14244269638     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200503000-00008     Document Type: Review

References (69)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122:1-9.
2. Quinton PM. Missing CI conductance in cystic fibrosis. Am J Physiol 1986; 251:C649-C652.
3. Davidson AGF. Gastrointestinal disease in cystic fibrosis. In: Hodson ME, Geddes DM, editors. Cystic fibrosis. London: Arnold; 2000. pp. 261-288.
4. Bell SC. Optimizing nutrition in cystic fibrosis. J Cyst Fibros 2002; 1:47-50.
5. Doring G, Bellon G, Knight R. Immunology and cystic fibrosis. In: Hodson ME, Geddes DM, editors. Cystic fibrosis. London: Arnold; 2000. pp. 109-140.
6. Rogers GB, Carroll MP, Serisier DJ, et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42:1-8.
7. Keicher U, Koletzko B, Reinhardt D. Omega 3 fatty acids suppress the enhanced production 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur J Clin Invest 1995; 25:915-919.
8. Greally P, Hussein MJ, Sampson AP, Price JF. Sputum TNF alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68:389-392.
9. 4 markedly elevated in the epithelial lining fluid of patients with CF. Am Rev Respir Dis 1993; 148:896-901.
10. Carpagnano GE, Barnes PJ, Geddes DM, et al. Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:1109-1112.
11. Sampson AP, Spencer DA, Green CP, et al. Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol 1990; 30:861-869.
12. Kronborg G, Hansen MB, Svenson M, et al. Cytokines in sputum and serum from patients with CF and chronic Pseudomanas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993; 15:292-297.
13. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075-1082.
14. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152:2111-2118.
15. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356-366.
16. Kuo PT, Huang NN, Bassett DR. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis. J Pediatr 1962; 60:394-403.
17. Biggemann B, Schuster LA, Griese M, et al. Status of plasma and erythrocyte fatty acids and vitamin A and E in young children with cystic fibrosis. Scand J Gastroenterol 1988; 23(Suppl. 143):135-141.
18. Hubbard VS, Dunn GD, di Sant'Agnese PA. Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect? Lancet 1977; 2:1302-1304.
19. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981; 34:1-7.
20. Farrell PM, Mischler EH, Engle MJ, et al. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985; 19:104-110.
21. Gibson RA, Teubner JK, Haines K, et al. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis. J Pediatr Gastroenterol Nutr 1986; 5:408-415.
22. Christophe A, Robberecht E, De Baets F, Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann Nutr Metab 1992; 36:304-312.
23. Levistre R, Lemnaouar M, Rybkine T, et al. Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. Biochim Biophys Acta 1993; 1181:233-239.
24. Christophe A, Robberecht E, De Franckx H, et al. Effect of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann Nutr Metab 1994; 38:40-47.
25. Roulet M, Frascarolo P, Rappaz I, Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997; 156:952-956.
26. Steinkamp G, Demmelmair H, Ruhl-Bagheri I, et al. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2000; 31:418-423.
27. Lepage G, Yesair DW, Ronco N, et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr 2002; 141:178-185.
28. De Vizia B, Raia V, Spano C, et al. Effect of an 8 month treatment with omega 3 fatty acids (EPA and DHA) in patients with cystic fibrosis. J Parenter Enter Nutr 2003; 27:52-57. A recent fish oil supplementation study in CF demonstrating improved lung function and decreased antibiotic use.
29. Walkowiak J, Wilzynski M, Boleslawska I, et al. The predominance of omega 6 fatty acids in cystic fibrosis despite low arachidonic acid levels. Acta Paediatr 2003; 92:1354-1355.
30. McKenna MC, Hubbard VS, Bieri JG. Linoleic acid absorption from lipid supplements in patients with cystic fibrosis with pancreatic insufficiency and in control subjects. J Pediatr Gastroenterol Nutr 1985; 4:45-51.
31. Henderson WR, Astley SJ, McCready MM, et al. Oral absorption of omega 3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994; 124:400-408.
32. Bhura-Bandali FN, Suh M, Man SFP, Clandinin MT. The delta F508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J Nutr 2000; 130:2870-2875.
33. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560-569. This study reports for the first time the fatty acid composition of tissues affected by CF. It found altered proportions of linoleic, arachidonic acid and DHA and an effect of the CFTR genotype on these.
34. Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr -/- mice. Proc Natl Acad Sci USA 1999; 96:13995-14000.
35. Kang JX, Man SF, Brown NE, et al. The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. Biochem J 1992; 285:725-729.
36. Strandvik B, Gronowitz E, Enlund F, et al. Essential fatty acid deficiency in relation to genotype in patients with CF. J Pediatr 2001; 138:650-655.
37. Christophe A, Robberecht E. Directed modification instead of normalization of fatty acid patterns in cystic fibrosis: an emerging concept. Curr Opin Clin Nutr Metab Care 2001; 4:111-113.
38. 2+ induced arachidonic acid release by epithelial cells. DNA Cell Biol 1997; 16:749-759.
39. Schwartz J, Weiss ST. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I). Eur Respir J 1994; 7:1821-1824.
40. Dry J, Vincent D. Effect of a fish oil diet on asthma: results of a 1-year double-blind study. Int Arch Allergy Appl Immunol 1991; 95:156-157.
41. Kew S, Banerjee T, Minihane AM, et al. Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am J Clin Nutr 2003; 77:1287-1295.
42. Wallace FA, Miles EA, Calder PC. Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects. Br J Nutr 2003; 89:679-689.
43. 2 production and T-cell function after fish-oil supplementation: response to antioxidant co-supplementation. Am J Clin Nutr 2003; 78:376-382.
44. Healy DA, Wallace FA, Miles EA, et al. The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 2000; 35:763-768.
45. Miles EA, Banerjee T, Dooper MWBW, et al. The influence of different combinations of α-linolenic acid, stearidonic acid and EPA on immune function in healthy young male subjects. Br J Nutr 2004; 91:893-903.
46. Calder PC. Polyunsaturated fatty acids, inflammation and immunity. Lipids 2001; 36:1007-1024.
47. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003; 38:342-352. A recent review of the anti-inflammatory mechanisms of action of long chain n-3 fatty acids and of their clinical applications.
48. Yaqoob P. Fatty acids as gatekeepers of immune cell regulation. Trends Immunol 2004; 24:639-645. A recent review of the anti-inflammatory and immunomodulatory mechanisms of action of n-3 fatty acids.
49. Yaqoob P. Lipids and the immune response: from molecular mechanisms to clinical applications. Curr Opin Clin Nutr Metab Care 2003; 6:133-150.
50. Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 1983; 117:282-288.
51. Lee TH, Mencia-Huerta JM, Shih C, et al. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene-B5 and the double lipoxygenase products. J Biol Chem 1984; 259:2383-2389.
52. Serhan CN, Clish CB, Brannon J, et al. Anti-inflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: A novel mechanism for NSAID and n-3 PUFA therapeutic actions. J Physiol Pharmacol 2000; 4:643-654.
53. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med 2000; 192:1197-1204.
54. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 2002; 196:1025-1037.
55. Hong S, Gronert K, Devchand P, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autocoids in anti-inflammation. J Biol Chem 2003; 278:14677-14687.
56. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infitration and pro-inflammatory gene expression. J Biol Chem 2003; 278:43807-43817.
57. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101:8491-8496.
58. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 32:265-271.
59. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991; 121:547-555.
60. Caughey GE, Mantzioris E, Gibson RA. The effect on human tumor necrosis factor alpha and interleukin 1 production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63:116-122.
61. Trebble T, Arden NK, Stroud MA. Inhibition of tumour necrosis factor alpha and interleukin-6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 2003; 90:405-412.
62. Lo CJ, Chiu KC, Fu M. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res 1999; 82:216-221.
63. Lo CJ, Chiu KC, Fu MJ. Fish oil modulates macrophage P44/42 mitogen-activated protein kinase activity induced by lipopolysaccharide. J Parenter Enter Nutr 2000; 24:159-163.
64. Novak TE, Babcock TA, Jho DH, et al. NF-kappaB inhibition by n-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol 2003; 284:L84-L89.
65. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004; 23:71-78.
66. Kurlandsky LE, Bennick MR, Webb PM, et al. The absorption and effect of dietary supplementation with omega 3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994; 18:211-217.
67. Tuxen-Mengedoht M, Koletzko B, et al. Fish oil therapy in cystic fibrosis a randomized clinical trial. Clin Nutr 1999; 18(Suppl. 1):107.
68. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenic role for leukotriene B4. Lancet 1993; 342:465-469.
69. Beckles Willson N, Elliott TM, Everard ML. Omega 3 fatty acids (from fish oils) for cystic fibrosis. Cohrane Review. In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley and Sons Ltd.; 2003. A recent systematic review of fish oil supplementation studies in CF. However, only two studies were considered because other studies did not fit the inclusion criteria or were identified as being of poor quality. The more recent supplementation study of De Vizia et al. [28*] was not considered as it was published after the review.